University of Colorado Cancer Center
David Wagner serves as an Associate Professor in the Department of Medicine and Department of Neurology at the University of Colorado Anschutz Medical Campus since April 2008. In addition, David holds the position of Chief Scientific Officer at Op-T-Mune, Inc. since April 2017, where David has played a pivotal role in developing an FDA-approved drug for clinical trials aimed at treating type 1 diabetes and is awaiting FDA approval for a drug targeting late-stage COVID-19 patients. David co-founded Op-T LLC in April 2017, a startup biotech company focused on diagnostics for autoimmune diseases and therapeutic strategies for managing autoimmune inflammation. David's career in scientific leadership began at Op-T-Mune Inc. from June 2010 to April 2017. David earned a PhD in Biomedical Sciences from East Tennessee State University from 1987 to 1994.
This person is not in the org chart
This person is not in any teams
This person is not in any offices